Merck writes off hepatitis C drug | Chemical & Engineering News
Volume 95 Issue 10 | pp. 14-15 | Concentrates
Issue Date: March 6, 2017

Merck writes off hepatitis C drug

Department: Business
Keywords: finance, hepatitis C, uprifosbuvir

Merck & Co. has decided to write off its R&D program for uprifosbuvir, a nucleotide prodrug in Phase II development for treating hepatitis C. Merck acquired the compound when it purchased Idenix Pharmaceuticals for $3.9 billion in 2014. Recent changes in the pricing and sales outlook for the competitive hepatitis C market caused Merck to reassess its prospects and the drug’s value. As a result, the company will take a $2.9 billion pretax charge against 2016 earnings. Merck says it will continue to evaluate options for the uprifosbuvir clinical development program.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment